Response heterogeneity of EGFR and HER2 exon 20 insertions to covalent EGFR and HER2 inhibitors

Insertion mutations in EGFR and HER2 both occur at analogous positions in exon 20. Non-small cell lung cancer (NSCLC) patients with tumors harboring these mutations seldom achieve clinical responses to dacomitinib and afatinib, two covalent quinazoline-based inhibitors of EGFR or HER2, respectively....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Res
Main Authors: Kosaka, Takayuki, Tanizaki, Junko, Paranal, Raymond M., Endoh, Hideki, Lydon, Christine, Capelletti, Marzia, Repellin, Claire E., Choi, Jihyun, Ogino, Atsuko, Calles, Antonio, Ercan, Dalia, Redig, Amanda J., Bahcall, Magda, Oxnard, Geoffrey R., Eck, Michael J., Jänne, Pasi A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5596996/
https://ncbi.nlm.nih.gov/pubmed/28363995
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-16-3404
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados